Thyroid skeletal metastasis: pain management with verteblation

2017 ◽  
Vol 9 (1) ◽  
pp. e2-e2 ◽  
Author(s):  
Gianluigi Orgera ◽  
Miltiadis Krokidis ◽  
Alberto Rebonato ◽  
Marcello Andrea Tipaldi ◽  
Luca Mascagni ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Pain Management ◽  
Thyroid Carcinoma ◽  
Metastatic Disease ◽  
Percutaneous Vertebroplasty ◽  
Skeletal Metastasis ◽  
Spine Metastasis ◽  
Effective Measure ◽  
Novel Technique ◽  
Metastatic Lesions

The combination of percutaneous vertebroplasty with radiofrequency ablation (verteblation) has not shown to be an effective measure of pain management in patients with metastatic lesions of the spine. The use of this novel technique has not been previously described in metastatic disease from thyroid cancer. We would like to report our experience after treating a patient affected by a thyroid carcinoma and an osteolytic spine metastasis. The patient suffered from life-limiting pain and was successfully treated with a combination of vertebroplasty and radiofrequency ablation. This case shows that the indications of verteblation may be expanded in the palliative treatment of metastatic disease from thyroid carcinoma.

Percutaneous Vertebroplasty for Pain Management in Patients with Multiple Myeloma: Is Radiofrequency Ablation Necessary?

2013 ◽  
Vol 37 (1) ◽  
pp. 203-210 ◽  
Author(s):  
Gianluigi Orgera ◽  
Miltiadis Krokidis ◽  
Marco Matteoli ◽  
Gianluca Maria Varano ◽  
Giacinto La Verde ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Radiofrequency Ablation ◽  
Pain Management ◽  
Percutaneous Vertebroplasty

scholarly journals Fatal outcome of a young woman with papillary thyroid carcinoma and graves' disease: possible implication of "cross-signalling" mechanism

2008 ◽  
Vol 52 (7) ◽  
pp. 1194-1200 ◽  
Author(s):  
Graciela A. de Cross ◽  
Horacio Suarez ◽  
Fabián Pitoia ◽  
Daniel Moncet ◽  
María Vanegas ◽  
...  
Keyword(s):  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Metastatic Lymph Node ◽  
Fatal Outcome ◽  
Point Mutations ◽  
Papillary Thyroid ◽  
Signaling Mechanism ◽  
Metastatic Lesions

A 29 yrs-old patient was referred to our hospital due to generalized convulsions. She had hyperthyroidism treated with methimazole. Her MRI showed 4 metastatic lesions in the brain. She had a goiter with a "cold" nodule and a palpable ipsilateral lymph node. The FNAB disclosed a papillary thyroid carcinoma. Under 5 mg of MMI treatment, she had a subclinical hyperthyroidism and TRAb were 47.8% (n.v. < 10%). The CT scan also showed lung metastasis. She underwent a total thyroidectomy with a modified neck dissection and she received an accumulated radioiodine dose of 700 mCi during the following two years. She died from the consequences of multiple metastatic lesions. Studies were performed in DNA extracted from paraffin-embedded tissue from the tumor, the metastatic lymph node and the non-tumoral thyroid. The genetic analysis of tumoral DNA revealed point mutations in two different genes: the wild type CAA at codon 61 of N-RAS mutated to CAT, replacing glycine by histidine (G61H) and the normal GCC sequence at codon 623 of the TSHR gene was replaced by TCC, changing the alanine by serine (A623S). In the non-tumoral tissue no mutations were found. In vitro studies showed a constitutive activation of the TSHR. It is very probable that this activating mutation of the TSHR is unable to reach the end point of the PKA cascade in the tumoral tissue. One possibility that could explain this is the presence of a cross-signaling mechanism generating a deviation of the TSH receptor cascade to the more proliferative one involving the MAPKinase, giving perhaps a more aggressive behavior of this papillary thyroid cancer.

scholarly journals Radiofrequency Ablation to Treat Loco-Regional Recurrence of Well-Differentiated Thyroid Carcinoma

2014 ◽  
Vol 15 (6) ◽  
pp. 817 ◽  
Author(s):  
Sun Jin Lee ◽  
So Lyung Jung ◽  
Bum Soo Kim ◽  
Kook Jin Ahn ◽  
Hyun Seok Choi ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Thyroid Carcinoma ◽  
Differentiated Thyroid Carcinoma ◽  
Regional Recurrence ◽  
Well Differentiated

Preoperative considerations

2021 ◽  
pp. 185-192
Author(s):  
Kenneth Fiala ◽  
Joshua Martens ◽  
Alaa Abd-Elsayed
Keyword(s):  
Radiofrequency Ablation ◽  
Pain Management ◽  
Sacroiliac Joint ◽  
Joint Pain ◽  
Surgical Approaches ◽  
Risk Of Infection ◽  
Fusion Surgery ◽  
Steroid Injections ◽  
Nonsurgical Management ◽  
Sacroiliac Joint Fusion

Sacroiliac joint fusion surgery is an option for patients whose sacroiliac joint pain has been refractory to conservative pain management. A good candidate for fusion surgery is one who has completed all appropriate nonsurgical management efforts, including physical therapy, intraarticular sacroiliac steroid injections, oral analgesics, and radiofrequency ablation of sacral nerve roots, without experiencing any improvement in pain. This chapter covers candidate selection, the two main surgical approaches used for this fusion surgery (open and minimally invasive), anticoagulation guidelines, and the risk of infection and complications. Before surgery it is very important to make sure the patient understands the risks of the surgery as well as the potential for success.

scholarly journals Clinical value of matrix metalloproteinase-2 and -9 in ultrasound-guided radiofrequency ablation treatment for papillary thyroid carcinoma

2020 ◽  
Vol 48 (8) ◽  
pp. 030006052091758
Author(s):  
Qunyan Pan ◽  
Tao Yuan ◽  
Qian Ding
Keyword(s):  
Radiofrequency Ablation ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Matrix Metalloproteinase ◽  
Enzyme Linked Immunosorbent Assay ◽  
Papillary Thyroid ◽  
Affecting Factors ◽  
Ultrasound Guided ◽  
Lesion Diameter ◽  
Preoperative Serum

Objective This study aimed to investigate serum matrix metalloproteinase (MMP)-2 and MMP-9 levels in patients with papillary thyroid carcinoma (PTC). Methods Forty-one patients with PTC undergoing ultrasound-guided radiofrequency ablation (RFA) and 56 controls were included. Serum MMP-2 and MMP-9 levels were determined by enzyme-linked immunosorbent assay before and after surgery. Potential affecting factors were evaluated by logistic regression analysis. Results Serum MMP-2 and MMP-9 levels were significantly higher in PTC patients compared with controls, and decreased significantly after surgery. According to receiver operating characteristic curve analysis, diagnostic values for preoperative serum MMP-2 and MMP-9 levels were 82.4% and 86.6%. There was no contrast-agent perfusion in the ablation zone in 88.5% of lesions, and enhancement within or at the lesion edge in 11.4%. The volume reduction at 3 months’ follow-up was >40%. Age, microcalcification, irregular shape, and lesion diameter and number were influencing factors for PTC. Age, and lesion diameter and number were independent risk factors, while calcification and morphology were protective factors. Conclusion Serum MMP-2 and MMP-9 levels have important clinical values for the diagnosis and treatment of PTC by RFA. Preoperative serum MMP-2 and MMP-9 levels, combined with other affecting factors, contribute to disease prognosis.

Sign in / Sign up

Export Citation Format

Share Document